Facebook
Twitter
YouTube
RSS
  • Home
  • About Us
    • Who we are
    • Mission and Vision
    • Time Line
    • Advisory Council
  • Our Work
    • Prevention Policy
    • Treatment Policy
    • Human Rights
  • Publications
    • Bulletins
    • Policy Brief
  • Campaigns
  • Multimedia and Photos
    • Gallery Photos
    • Gallery Videos
  • News
  • Contact
News
10Apr

Activists file post grant opposition to challenge a patent prevents purchase of cheaper treatment for hepatitis C

In GTPI’s opinion, this concession is undeserved. The main argument is that the patent
lacks sufficiency disclosure, ie, it does not have the level of detail necessary for the
technology described therein to be reproduced by a person skilled in the art. This is
fundamental to justify the granting of the patent.

Read more
News
23Aug

Protests in Brazil exposures Gilead’s greed to block generic sofosbuvir

In Rio de Janeiro activists demand INPI to reject the patent. In São Paulo, activists remembered the deaths due to lack of access in front of Gilead’s office.

Read more
News
4May

Gilead’s patent application on sofosbuvir rejected in Brazil

The Working Group on Intellectual Property of the Brazilian Network for Integration of Peoples (GTPI/Rebrip), a coalition of civil society organizations and activists coordinated by the Brazilian Interdisciplinary Aids Association (ABIA), filed several patent oppositions in this case.

Read more
ABIA – BRAZILIAN INTERDISCIPLINARY AIDS ASSOCIATION
GLOBAL AIDS POLICY WATCH


Av. Presidente Vargas, 446 - 13º andar, 20071-907
Centro - Rio de Janeiro - RJ

+55 (21) 2223-1040


Hivos
Hivos
  • Home
  • About Us
    • Who we are
    • Mission and Vision
    • Time Line
    • Advisory Council
  • Our Work
    • Prevention Policy
    • Treatment Policy
    • Human Rights
  • Publications
    • Bulletins
    • Policy Brief
  • Campaigns
  • Multimedia and Photos
    • Gallery Photos
    • Gallery Videos
  • News
  • Contact